| Current Price | $2.17 | Mkt Cap | $1.1B |
|---|---|---|---|
| Open | $2.18 | P/E Ratio | 0.00 |
| Prev. Close | $2.17 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $2.13 - $2.21 | Volume | 4,725,645 |
| 52-Wk Range | $1.18 - $3.84 | Avg. Daily Vol. | 5,169,672 |
A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.
| Current Price | $2.17 | Mkt Cap | $1.1B |
|---|---|---|---|
| Open | $2.18 | P/E Ratio | 0.00 |
| Prev. Close | $2.17 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $2.13 - $2.21 | Volume | 4,725,645 |
| 52-Wk Range | $1.18 - $3.84 | Avg. Daily Vol. | 5,169,672 |
The best Bull and Bear pitches based on recency and number of recommendations.
Drug in Two Phase III trials with promising Phase II results. Drug could be used in combination with other drugs to treat 90% of cancers .A partnership or approval could be catalysts to increase the pps.
Still waiting for my stocks to go to zero. Lost so much, no point cashing out now....
Read the most recent pitches from players about GERN.
Recs
mrd0617
(< 20)
Submitted: 3/26/2022 4:27:27 PM :
Start Price:
$1.54
NASDAQ:GERN Score:
+50.10
Drug in Two Phase III trials with promising Phase II results. Drug could be used in combination with other drugs to treat 90% of cancers .A partnership or approval could be catalysts to increase the pps.
Recs
LastPlaceLenny
(26.81)
Submitted: 3/15/2019 2:46:17 AM :
Start Price:
$1.66
NASDAQ:GERN Score:
+16.35
Still waiting for my stocks to go to zero. Lost so much, no point cashing out now....
Recs
streetdan
(< 20)
Submitted: 9/9/2018 10:31:50 AM :
Start Price:
$6.15
NASDAQ:GERN Score:
-106.55
This company has found an effective cancer treatment that has only a relatively small, easily managed toxicity. It is on the frontier of not only being a potential stand alone agent, but also may improve other cancer agents when used in combination. They have therefore an agent that can disrupt cancers progression without significant harm to normal cells.
Find the members with the highest scoring picks in GERN.
SheepInvstr213 (< 20) Score: +595.18
The Score Leader is the player with the highest score across all their picks in GERN.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| SheepInvstr213 | < 20 | 3/9/2009 |
|
5Y | $4.59 | -53.29% | +507.72% | +561.01 | 0 Comment | |
| epc53 | 26.65 | 3/3/2009 |
|
NS | $3.85 | -44.29% | +489.67% | +533.95 | 0 Comment | |
| Dudeone | 49.77 | 3/12/2009 |
|
5Y | $4.32 | -50.35% | +458.41% | +508.76 | 0 Comment | |
| e2003 | 82.30 | 3/30/2009 |
|
1Y | $4.75 | -54.84% | +417.50% | +472.34 | 0 Comment | |
| kevleeyang | 61.07 | 1/23/2009 |
|
NS | $7.23 | -70.33% | +401.34% | +471.67 | 0 Comment | |
| js2776 | < 20 | 1/26/2009 |
|
3Y | $8.15 | -73.68% | +396.61% | +470.29 | 2 Comments | |
| yourfavoritepers | 86.78 | 1/26/2009 |
|
3W | $7.47 | -71.29% | +397.14% | +468.43 | 0 Comment | |
| dcfoolz | 73.39 | 1/26/2009 |
|
5Y | $7.47 | -71.29% | +397.14% | +468.43 | 0 Comment | |
| Lafleur526 | 40.70 | 1/26/2009 |
|
3W | $7.47 | -71.29% | +397.14% | +468.43 | 0 Comment | |
| SheepInvstr321 | 97.25 | 1/23/2009 |
|
5Y | $7.36 | -70.85% | +396.31% | +467.16 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
